INTRODUCTION
According to the National Cancer Institute, 5 year survival rates of cancer patients are the highest when cancer is detected and treated at an early, localized, stage. Currently, there are a number of different cancer-type specific biomarkers used to detect cancer at an early stage; however most of them are associated with alarmingly high false positive rates (FPRs). For example, ovarian cancer screening using the CA-125 biomarker (1) along with transvaginal ultrasonography has a sensitivity of ~90% but a FPR of 57% (2). Mammography for breast cancer screening has a FPR of 40-60% over 10 years of screening (3),
Cologuard ® for colorectal cancer screen has a FPR of 13.4% (4), and PSA for prostate cancer screening has a FPR of 20-30% when the test aims to detect >80% of cancers (5). False positive results, and sometimes screening methods themselves, tend to lead to invasive and uncomfortable procedures that are associated with risk to otherwise healthy individuals; e.g. radiation exposure during mammography and surgery or biopsy in the case of other tumor types. These unnecessary procedures, unfortunately, lead to adverse events in approximately 15% of cases (6) . High false positive rates along with high adverse event rates for follow-up procedures place a significant proportion of the healthy population at unnecessary risk.
Thus, an alternative and highly accurate non-invasive method for early cancer detection, especially a global test for multiple types of cancer, would both reduce the rate and impact of false positive results on otherwise healthy individuals, and could lead to substantial improvements in survival and quality of life of cancer patients.
Copy number variations (CNVs), like point mutations, are common and causal for a large proportion of cancer types (7, 8) . CNV based classification of tumor subtypes has been demonstrated previously, though these methods have been focused on gene level events and the stratification of tumors from a single organ system into clinically relevant subtypes -rather than assignment of a CNV profile to a tissue of origin (9) (10) (11) In this light, we explore the potential for ctDNA CNV detection for cancer screening by evaluating the ability to detect and differentiate tumor types via large tumor CNV events (5 megabases or greater) that are theoretically detectable via ctDNA sequencing (15). We demonstrate that, for many tumor types, including those not necessarily enriched with CNV events, it is theoretically possible to accurately detect and classify tumor types via large ctDNA detectable tumor-derived CNVs.
RESULTS

Sample Clustering Using SAX Representation
First, we divided the human genome into segments of sizes 5, 6, 7.5, 10, 30, 40, 60, 75, and 100 megabases -segment sizes representing a range of tumor-derived CNV event sizes (7) tumor types. These results suggest that classification of tumor type by CNV profile is possible, though requires more sophisticated methodology to account for heterogeneity within tumor types and similarity across tumor types (10).
Nearest Neighbor Classification
Given the promising but limited success of unsupervised clustering for cancer type classification, we sought to determine whether cancer type can be determined by a k nearest neighbor approach, which should account for enrichment of cancer types within intermixed clusters. When the nearest neighbor approach was utilized in attempt to determine cancer type or origin, an overall accuracy of 0.691 was observed at the 100Mb segment size. At the 5 Mb segment size the overall accuracy of cancer type prediction was 0.694 -a non-significant improvement over the accuracy at 100Mb segment size (Supplemental Table 2 ). Again, most of the poor performers were cancer types with flat CNV profiles while kidney cancers and GBM performed the best (Table 1) . This is consistent with the finding that KIRC and GBM also formed more or less consistent clusters during simple clustering. Thus, while the nearest neighbor approach readily distinguished cancer from normal profiles, at CNV resolution detectable by ctDNA sequencing, accuracy remains insufficient for differentiation of tumor types from one another.
Random Forest Classification
Finally, we utilized a random forest classification model to simulate the (near) optimal classification performance of the ctDNA biomarker (23). The model had an overall accuracy of 0.78 and 0.74 when classifying all tumor types at segment sizes of 5Mb and 100Mb respectively. ROC curves at 5Mb and 100Mb segment size are plotted in Figure 2 for the 11 major solid tumor types, and demonstrate significant differences in performance across tumor types. Additional ROC curves for all thresholds and cancer types can be found in the Supplemental Data. Figure 2 demonstrates an overall improvement in the predictive power across most cancer types at the greater segment size resolution, but once again the improvement when increasing resolution from 100Mb to 5Mb segments is not dramatic. Certain cancer types, such as OV, BRCA, GBM and KIRC are consistently and accurately (~95%) assigned to the correct tumor type across all segment sizes. While others, apparently those of squamous histology, such as HNSC, LUSC, and BLCA show a considerable improvement (~5% increase in accuracy) in predictive value as segment size detection resolution is improved. Thus, while cancer profiles can be readily distinguished from normal profiles, determination of the tissue of origin shows variability in performance across tumor types and segment size resolution.
The optimal performance for the different cancer types, based on the point on the ROC curve nearest to 100% specificity and sensitivity is presented in Table 1 and Supplemental 
Tumor Misclassification
Given that our prediction model does not correctly classify all the tumor samples, we investigated whether misclassifications were driven by biological relationships or were true classification errors. The misclassification heat map at the 5 Mb segment size threshold is displayed in Figure 3 , additional heat maps for other size thresholds are available as Supplementary Data. Many misclassifications were true errors -cancer samples being classified as normal samples (23.4% of errors) or as Breast invasive carcinomas (12.8% of errors). These errors are largely derived from cancer types such as Thyroid Carcinomas that have very poor performance overall and have flat CNV profiles that are difficult to distinguish from normal samples ( Supplemental Table 4 ). Breast cancers tend to be diverse with respect to their cell type of origin and contain molecularly distinct subtypes (10), and thus may mimic CNV profiles of other tumor types. While breast cancer samples themselves were classified accurately, many errors were derived from other tumor types being classified as breast cancer. Given that breast cancer was the largest sample set overall, the imbalance of tumor samples per type is potentially driving this misclassification bias.
For cancer types without flat CNV profiles, misclassification tended to cluster based on tissue of origin or molecular subtype. For example, squamous cell cancers like LUSC, HNSC, ESCA and CESC show similar misclassification patterns and are often misclassified for one another (Figure 3) Interestingly, the tumor types that could be most effectively identified via CNV profile did not necessarily align with the M-class (mutation class) vs. C-class (copy number variant class) tumor types as determined by another pan-cancer study (28). For example, although KIRC is an M-class tumor, it was among the most effectively classified tumor types based on its CNV profile. While KIRC is not broadly copy number aberrant, loss of the short arm of chromosome 3 (3p) (29) containing genes like VHL, PBRM1, BAP1 and SETD2, is highly predictive of KIRC -given it is observed in almost 90% of KIRC cases.
Thus, the promise of this approach is not necessarily limited to C-class tumor types.
Some potential challenges for the implementation of ctDNA CNV detection for early cancer screening are not fully addressed by this in silico analysis. For example, it will be necessary to understand and override the issue of sample variability in order to achieve the accurate identification of CNVs via ctDNA. While we have made a conservative estimate of this variability, robust sequencing-depth normalization schemes will likely be necessary to achieve this level of variance. Moreover, it is presumed, but not known, whether CNVs predictive of cancer are present in early stage tumors. The battery of tumor profiles used in this analysis, derived from The Cancer Genome Atlas (http://cancergenome.nih.gov/), contain many late stage tumors. These analyses suggest that cancer screening via ctDNA based CNV detection should be attempted in diverse and larger patient cohorts.
METHODS
Copy Number Variation Data
We downloaded whole genome copy number variation data, generated by the Tumor Cancer Genome Specifically, we downloaded the segmentation files which contain information about the copy number of segmented genomic data produced by various algorithms like GLAD and CBS(31, 32) . Variants in each sample were first run through the SG-ADVISER CNV annotation pipeline (33) and then variants with an allele frequency of >1% in the 1000 Genomes (34) or the Wellderly (35, 36) cohorts were filtered out.
Data Representation
We adapted the SAX transformation (20) to represent the CNV data in a concise format while not losing any critical information. We first divided chromosomes 1-22 into segments of sizes 5, 6, 7.5, 10, 30, 40, 60, 75, 100 Mega bases. For each of the segments we calculated the average segment duplication value.
This average segment duplication value was then mapped to an appropriate letter representation.
Specifically, any value above 0.4 was mapped to 'e', values between 0.2 and 0.4 were mapped to 'd', values between -0.2 and 0.2 were mapped to 'c', values between -0.2 and -0.4 were mapped to 'b' and any value below -0.4 were mapped to 'a'. We chose a cardinality of 5 to be able to represent normal or 2 copies, 1 copy amplification, more than 2 copy amplification, 1 copy deletion and 2 copy deletion of the genomic segment.
Prediction Methods
The SAX transformed data was used to train machine learning models which could distinguish a normal sample from a cancer sample and also predict the type of the cancer as described by TCGA. We used random forests which is an ensemble learning method and the KNN (k-nearest neighbors) method which is a simpler pattern recognition algorithm.
The standard k-Nearest Neighbor algorithm was implemented using custom code in R. Briefly, we calculated distances between each of the SAX transformed samples using a modified hamming distance metric where the distance between adjacent letters was fixed as 0.5 and any other changes were fixed as 1.
The data was then randomly split into a training set (75%) and a test set (25%). For classification the custom distance metric was used to find k training samples closest to the test sample and the majority class in the k samples was assigned to the test sample. k was set as the square root of the total number of samples.
A separate random forest model was trained to optimize overall accuracy for each segment size threshold using a 10 fold cross validation training scheme, each model contained 100 trees and the optimal number of variables randomly sampled as candidates at each split in the trees was determined heuristically.
For tumor clustering we used the segments marked as important by the random forest model. Then we used the modified hamming distance described earlier to calculate the distances for the clustering. Each column in the heat map corresponds to a sample, and the rows represent the important segments identified by the random forest. Each cell has been colored red for a gain and blue for a loss.
For the tumor misclassification heat maps the color scale was used to represent the percentage of misclassification as another tumor type or normal with white being 0% and dark blue being 100% 
Theoretical Power of CNV Detection Calculations
To calculate the theoretical limit of detecting CNVs we used a negative binomial distribution to model the sequencing of circulating DNA and subsequent read mapping. Generally, sequencing data is affected by biases in genome composition, sequencing and mapping and thus a negative binomial distribution does a better job at modelling the sample variance as compared to a Poisson distribution (37). We used two separate negative binomial models, for the first we used the following definition of the probability mass function (pmf)
Where X is the random variable denoting the number of successes before 'r failures' or in this case number of reads mapped to the genomic segment of interest; p is the probability of one success i.e. the probability of mapping a read to that genomic segment calculated as 1/(Number of Segments); r, the number of failures, is calculated as (1-p)(Total number of reads) denoting the number of reads mapped to any other genomic region. For the second model we used an alternative formulation of the negative binomial distribution represented as the following pmf 
In this case r is referred to as the "dispersion parameter" or the "shape parameter" and m is the mean of the distribution calculated as (Total number of reads)/(Number of segments). The variance for this model is given by . We fixed the variance as twice the mean value, thus getting an estimate for 'r' and using that for the model. This was done in order to simulate an arbitrarily large variance. For both these models we then calculated the right tail of the pmf for X being equal to the expected number of counts at a segment in case of a 1 copy duplication event given the mean being equal to the expected counts at the segment in case of a normal sample, thus getting a p-value. We performed these calculations at various read depths and circulating tumor DNA representing 0.1%, 1% and 10% fraction of the total circulating DNA in the sample.
Software
Data filtration and SAX transformations were performed using custom scripts in python. All models were built using R v3.1.1. The 'caret' library in R was used to train the random forest models. ROC curves denoting the performance of the models were plotted using the library 'pROC'. Heat maps were plotted using the 'gplots' library. All calculations for the theoretical limit of CNV detection were performed using R version 3.1.1 as well. seen that there is an overall increase in the AUC values when going from a 100 Mb segment size to 5 Mb segment size in both Cancer vs Normal and Cancer Type prediction. The increase in AUC, however, is not dramatic and reflects the robustness of this method at various size resolutions.
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Figure 3: Heat map cluster of tumor types by misclassification frequency
Every column has one cancer type and each row displays the misclassification frequency of that cancer type to the one represented by the row. Correct classifications are set to 0 to highlight the misclassifications. Color indicates the frequency of misclassification with darker color being a higher frequency. Cancers seem to cluster according to their cells of origin and most misclassifications are to 1 cancers with similar cell type. Cancers like THCA, PAAD and PRAD that have low CNV burden are the hardest to detect from Normal samples.
Figure 4: Theoretical power of CNV Detection
CNV size (Kb) detectable with a p-value < 0.01 is plotted against the number of reads required to do so.
Each curve represents the amount of ctDNA as a percentage of total circulating DNA. Darker colored curves represent calculations using a Negative Binomial (NB) model and lighter colors represent calculations using a NB model with variance fixed as twice the mean. 
